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The cytosolic helicase retinoic acid-inducible gene-I
(RIG-I) initiates immune responses to most RNA vi-
ruses by detecting viral 50-triphosphorylated RNA
(pppRNA). Although endogenous mRNA is also 50-tri-
phosphorylated, backbone modifications and the
50-ppp-linked methylguanosine (m7G) cap prevent im-
munorecognition. Here we show that the methylation
statusofendogenouscappedmRNAat the50-terminal
nucleotide (N1)wascrucial to preventRIG-I activation.
Moreover,we identifiedasingleconservedaminoacid
(H830) in the RIG-I RNA binding pocket as the medi-
ator of steric exclusion of N1-2
0O-methylated RNA.
H830A alteration (RIG-I(H830A)) restored binding of
N1-2
0O-methylated pppRNA. Consequently, endoge-
nous mRNA activated the RIG-I(H830A) mutant but
not wild-type RIG-I. Similarly, knockdown of the
endogenous N1-2
0O-methyltransferase led to consid-
erable RIG-I stimulation in the absence of exogenous
stimuli. Studies involving yellow-fever-virus-encoded
20O-methyltransferase and RIG-I(H830A) revealed
that viruses exploit this mechanism to escape RIG-I.
Our data reveal a new role for cap N1-2
0O-methylation
in RIG-I tolerance of self-RNA.
INTRODUCTION
Most highly pathogenic and emerging viruses are RNA genome-
based viruses, giving rise to zoonotic and epidemic diseases
(e.g., influenza) or causing viral hemorrhagic fever (yellow fever,
dengue fever, Lassa fever, Ebola disease) (Bray, 2008). The first
barrier against invasion of RNA viruses is a cytosolic innate intra-
cellular defense response that is present in all cell types and isinitiated by activation of the viral RNA-sensing innate immune re-
ceptors RIG-I (retinoic acid-inducible gene 1I) and MDA5 (mela-
noma differentiation-associated protein 5) in the cytosol (Gitlin
et al., 2006; Kato et al., 2006; Loo et al., 2008). Upon sensing of
viral RNA, RIG-I or MDA5 induces type I interferon (IFN) secretion
leading to upregulation of antiviral IFN-induced proteins in the in-
fected and neighboring cells, which inhibits virus replication or
protects against new infection. Further downstream events
attract immune cells and trigger the adaptive immune response.
Discrimination of a few viral RNAmolecules from the abundant
host RNA in the cytosol occurs by detection of unusual structures
or modifications of the viral RNA. The structural features leading
to recognition by MDA5 have remained elusive. By contrast,
because of high-resolution structures of RIG-I/ligand complexes,
the mechanism of RNA recognition by RIG-I is well understood
(Civril et al., 2011; Jiang et al., 2011; Kowalinski et al., 2011; Lu
et al., 2010; Luo et al., 2011;Wang et al., 2010). RIG-I is activated
by double-stranded 50-triphosphorylated RNA (ppp-dsRNA)
(Hornung et al., 2006; Pichlmair et al., 2006; Schlee and Hart-
mann, 2010; Schlee et al., 2009). Like most viral RNAs, endoge-
nous mRNA and RNA polymerase III transcripts are also 50-tri-
phosphorylated. However, mRNAs of eukaryotes possess a
cap structure consisting of a triphosphorylated 50 end that is
50-50 linked to a guanosine methylated at N7 (
m7G) (Figure 1A).
The m7G cap is essential for eIF4a-dependent mRNA-dependent
protein translation from yeast to vertebrates. 20O-methyl modifi-
cations at N1 and N2 are conserved features of mRNA cap struc-
tures of higher eukaryotes (Banerjee, 1980) but haven’t been
implicated in mRNA translation control so far (Be´langer et al.,
2010). A number of differences between eukaryotic RNA andmi-
crobial RNAs havebeendescribed that explain thediscrimination
of self and non-self by RIG-I. Apart from the presence of a
50-triphosphate moiety in fully base-paired regions in various
microbial RNA species, this also includes certain modifications
in eukaryotic RNAs that exert an inhibitory function on otherwise
stimulatory RNAmolecules. This includes backbone and nucleo-
base modifications in eukaryotic RNAs, a well as m7G capImmunity 43, 41–51, July 21, 2015 ª2015 Elsevier Inc. 41
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Figure 1. 20O-Methylation at N1 Position of RNA Critically Determines the Abolition of RIG-I Activation
(A) The chemical structure of cap structures as contained in eukaryotes’ mRNA is presented (m7GpppNmNm). Important structural features are labeled. The cap2
structure, which occurs only in higher eukaryotes’ mRNA, consists of a G, 50-50 triphosphate linked to N1, with methylation at N7 of the G residue. N1 and N2 are
20O-methylated.
(B and C) Chloroquine-treated human PBMCs were stimulated with the indicated synthetic RNA oligonucleotides (see also Table S1 and Figure S2) at con-
centrations of 2.5 nM and 5 nM (B) or a dose titration was performed (C). Before stimulation, RNA oligonucleotides were hybridized with the complementary RNA
(AsGA) to blunt-ended double-stranded RNA. IFN-a production was analyzed 20 hr after stimulation. Data from four donors are depicted as mean values + SEM.
(D) Murine bone-marrow-derived dendritic cells fromMDA5- or RIG-I-deficient or wild-type mice were stimulated with indicated RNA ligands (50 nM) and murine
IFN-a was determined by ELISA (linear range limit: 80 pg/ml) 20 hr after transfection. One representative experiment out of two is shown. Error bars indicate SD.modification of eukaryotic mRNAs (Hornung et al., 2006; Pichl-
mair et al., 2006). The relative contribution of these activating or
inhibiting signatures in putative RIG-I ligands remains to be
determined, especially in light of the fact that in vitro transcription
was used to study the impact of the latter modifications (Goubau
et al., 2014; Schlee et al., 2009; Schmidt et al., 2009; see Supple-
mental Experimental Procedures). In the present study, by using
synthetic pppRNA, we re-assessed the impact of m7G on RIG-I
stimulation and analyzed also the influence of single modifica-
tions (including G methylation at N7 and 2
0O-methylation of the
N1 and N2 position of the RNA) on the interaction with RIG-I.
We found that a m7G cap alone could only partially reduce
RIG-I stimulation at low RIG-I ligand concentrations, whereas42 Immunity 43, 41–51, July 21, 2015 ª2015 Elsevier Inc.the 20O-methylation of the 50-terminal nucleotide (N1) entirely
abrogated RIG-I activation even at high ligand concentrations.
Structure-guided mutational analysis led to the identification of
a highly conserved histidine (H830) in the RNA binding domain
of RIG-I, which is dispensable for RIG-I activation but mediates
steric exclusion of N1-methylated RNA. We furthermore provide
evidence that endogenous RNA stimulated RIG-I in the absence
of endogenous cap1 20O-methylation or if H830 was mutated.
Furthermore, we demonstrated that RNA viruses exploited this
tolerance mechanism to avoid recognition by RIG-I. The 100%
conservation of this ‘‘licensing’’ histidine position in RIG-I among
vertebrates and even sea anemone RIG-I highlights a funda-
mental role of this self-RNA tolerance mechanism in evolution.
As such, this is the first study showing the biological relevance of
endogenous cap 20O-methylation and the corresponding en-
zymes for immune tolerance of self-RNA, a pathway that is rele-
vant for any cell type in the body.
RESULTS
20O-Methylation at the N1 Position of RNA Critically
Determines the Abolition of RIG-I Activation
Capping of mRNA is required for effective ribosomal translation.
Three forms of cap structures are known: cap0 is a N7-methyl
guanosine (m7G) linked to the gamma phosphate of the
50-triphosphate of RNA (m7GpppNN; N = nucleotide; Figure 1A);
cap1 is identical to cap0 except for an additional 20O-methyl
group at the N1 position (
m7GpppNmN); and cap2 carries a
second 20O-methyl group at the N2 position (
m7GpppNmNm).
Although the cap N7-methyl guanosine in cap structures is well
known to be required for effective ribosomal translation, the
impact of the 20O-methyl groups at N1 and N2 on translation is
unclear. So far, it has been described that replication of (+)
ssRNA viruses lacking the viral N1-2
0O-methyl transferase is
restricted by the type I IFN-induced, pppRNA binding protein
IFIT1 (Abbas et al., 2013; Daffis et al., 2010; Habjan et al.,
2013; Pichlmair et al., 2011). To study the impact of the different
components of cap structures on immunorecognition of RNA by
RIG-I, we established methods to generate well-characterized
24-mer RNA oligonucleotides with identical sequence and con-
taining a 50-triphosphate with additional single or combined fea-
tures of the cap0/1/2 structures (e.g., with or without guanosine
cap, N7-methylated guanosine cap, 2
0O-methyl at N1 or N2; see
Figures S2A–S2E and Table S1). These RNA oligonucleotides
were hybridized with complementary RNA (antisense RNA oligo-
nucleotide: AsGA; Table S1) resulting in short double-stranded
blunt-end RNA oligonucleotides (ppp-dsRNA). The double-
stranded RNA oligonucleotides were transfected into human
peripheral blood mononuclear cells (PBMCs) in the presence
of chloroquine, which eliminates endosomal TLR-mediated
recognition. In this setting, IFN-a induction by short ppp-dsRNA
is exclusively mediated by RIG-I (Schlee et al., 2009; Wang et al.,
2010). We found that 50ppp50-linked G (GpppGA) did not impair
RIG-I activation (Figure 1B), whereas N7-methylation of the
50ppp50-linked G (cap0 = m7GpppGA; Figure 1B) only partially
reduced IFN-a induction at the concentrations used (2.5 nM).
In dose response experiments, complete inhibition of RIG-I acti-
vation by m7G capwas seen at concentrations below 0.5 nM (Fig-
ure 1C). By contrast, a single 20O-methyl group at N1 (pppGmA)
completely abolished RIG-I activation at all RNA concentrations
tested (up to 15.8 nM; Figures 1B and 1C). The combination of
the 20O-methyl group at N1 and
m7G as in cap1 (m7GpppGmA;
Figure 1B) also showed no activity. However, 20O-methylation
at N2 with and without
m7G (m7GpppGAm, pppGAm) only partially
reduced the RIG-I activity (Figure 1B). These data reveal a domi-
nant role of the 20O-methyl group at N1 for the inability of RIG-I to
sense capped pppRNA. Stimulation of bone-marrow-derived
dendritic cells (BM-DCs) deficient for Ifih1 (encoding MDA5) or
Ddx58 (encoding RIG-I) with ligands comprising different cap
structures confirmed the exclusive detection of capped pppRNA
by RIG-I and the absolute inhibitory effect of 20O-methylation
(Figure 1D).TheAminoAcidH830 in theRNABindingDomain of RIG-I
Is Responsible for Steric Exclusion of
N1-2
0O-Methylated cap1 RNA
RIG-I is composed of two N-terminal signaling adaptor domains
(CARD), a helicase domain (DECH), and the C-terminal domain
(CTD), which was identified to harbor the pppRNA binding site
(Cui et al., 2008; Takahasi et al., 2008). The CTD possesses a
basic binding cleft with ppp-dsRNA-CTD interactions at amino
acids F853 (50-terminal base pair stacking), K858, H847, K861,
K888 (ppp binding), K907 (internucleotide phosphate binding),
and H830 (contact to 20OH of N1) (Lu et al., 2010; Wang et al.,
2010). We mutated selected amino acids of the binding pocket
of RIG-I to alanine and expressed the full-length RIG-I constructs
in HEK293blue cells, which lack RIG-I activity, if not primed by
type I IFN. The IP10 gene is known to be directly activated
by RIG-I (Brownell et al., 2014). IP10 secretion was studied as
a surrogate parameter of RIG-I activation after stimulation with
synthetic ppp-dsRNA or ppp-ssRNA (Figure 2A). The highly
conserved amino acids F853, K861, K888, and K907 (Figure S1),
which are part of the basic ppp-dsRNA binding cleft of the CTD
domain, were essential for RIG-I activation by ppp-dsRNA (Fig-
ure 2A). Although the highly conserved H830 is in contact with
20OH of N1, the H830A mutation did not decrease but instead
increased ppp-dsRNA-induced RIG-I stimulation (Figure 2A).
Immunoblot analysis confirmed that this increase was not due
to higher expression of the mutated RIG-I(H830A) (Figure 2B).
Indeed, its 100% conservation across all known vertebrate spe-
cies and sea anemone RIG-I (Figure S1) points to a key function
of H830 in RIG-I biology. Because H830 is not required for RIG-I
activation and given its position in proximity to N1, we speculated
that H830 might be involved in a steric interference of the
20O-methyl group (trans-C30-oriented) through its side chain
(Figure 2C; Wang et al., 2010). To address this hypothesis, we
performed a set of experiments in which we compared wild-
type (WT) RIG-I to RIG-I(H830A) by using different pppRNA
ligands. Indeed, in contrast to RIG-I(WT), the RIG-I(H830A)
mutant was still activated by ppp-dsRNA containing 20O-methyl
at N1 (pppGmA) and showed considerable activation in the pres-
ence of a complete cap1 structure (m7GpppGmA) (Figure 2D,
black bars).
By using a homogenous ligand interaction assay, we
analyzed the binding affinity of RIG-I(WT) and RIG-I(H830A)
to the different ppp-RNAs (Figures 2E–2G). Consistent with
reduced RIG-I-stimulating activity, binding of pppGmA to RIG-
I(WT) was 4.5-fold diminished in comparison to pppGA, and
50ppp50-linked m7G (m7GpppGA) also inhibited binding but to
a lower extent (2-fold) (Figures 2E and 2G). The binding of
cap1-bearing dsRNA (m7GpppGmA) to RIG-I(WT) was lower
than the detection limit of the assay (Figures 2E and 2G; Kd >
1,000 nM).
Similar to RIG-I(WT), the cap0 structure (m7GpppGA) reduced
binding of RIG-I(H830A) 2-fold, demonstrating that H830 does
not interfere with the m7G cap. In contrast to RIG-I(WT) and
consistent with the functional activity, binding of RIG-I(H830A)
to pppRNA with and without 20O-methylation at N1 was nearly
equal (Figures 2F and 2G). In line with this result, RNA with a
complete cap1 structure (m7GpppGmA) bound to RIG-I(H830A)
to an extent comparable to the non-20O-methylated cap0-
bearing RNA (m7GpppGA) (Figures 2F and 2G).Immunity 43, 41–51, July 21, 2015 ª2015 Elsevier Inc. 43
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Of note, pppGmA did still demonstrate some residual binding
to RIG-I(WT) in the Alphascreen assay although the assay
cannot resolve the binding site. One possible explanation for
this residual interaction with RIG-I(WT) could be non-productive
binding as reported previously (Marq et al., 2011). Here, RIG-I
binding was reported for ligands that could not activate
RIG-I or induce type I IFN. In particular, dsRNA with an over-
hanging 50-ppp-nucleotide (ppp(+1nt)-dsRNA) was observed
to be a weak competitor for blunt ppp-dsRNA (Marq et al.,
2011). To test whether N1-2
0O-methylation has similar effects
as a 50-ppp-overhang, we performed a competition assay as
described previously (Marq et al., 2011). We transfected
ppp-dsRNA as pppGA hybridized to asGA (pppGA+asGA)
mixed with a 24-fold excess of asGA (single-stranded control,
non-binder), pppGmA+asGA (blunt N1-2
0O-methylated), or
pppGA+asGA(1) (ppp(+1nt)-dsRNA, non-productive binder)
(Figure S2F; Marq et al., 2011). Although ppp(+1nt)-dsRNA,
as previously published, reduced RIG-I stimulation by ppp-
dsRNA 2-fold, no competitive inhibition via N1-2
0O-methyl-
ated ppp-dsRNA (pppGmA) could be detected. Thus, unlike
ppp(+1nt)-dsRNA, pppGmA binding does not seem to be suffi-
cient to block binding of pppGA in this setting.
Altogether, the results provide strong evidence that H830
impairs accurate binding of N1-2
0O-methylated RNA via steric
hindrance, leading to immune ignorance of 20O-methylated
pppRNA.
H830 and cap1 N1-2
0O-Methylation of Self RNA Prevent
Immunorecognition of Endogenous RNAs
The high conservation of H830 in RIG-I and its function in inter-
ference with accurate binding of 50-triphosphate RNA carrying
a 20O-methyl group at N1 suggest the existence of self-RNAmol-
ecules that depend on N1 methylation to evade recognition by
RIG-I. Although base-paired 50-triphosphate RNA is required
for RIG-I stimulation, GpppNN-RNA intermediates with such
RIG-I ligand properties might occur, causing some degree of
immune stimulation in the absence of 20O-methylation (or in
the presence of the mutated form of RIG-I that accepts 20O-
methylation). Indeed, we found that long-term expression of
RIG-I(H830A) in HEK293blue cells lacking RIG-I activity led to a
significant IP10 response in the absence of exogenous RIG-I
ligand (Figure 3A, black bars). To show that IP10 induction is
induced by endogenous RNA species, we overexpressed
RIG-I-CTD-FLAG in HEK293blue cells and purified endogenous
RNA bound to immunoprecipitated RIG-I-CTD-FLAG (Figure 3B,
left). RIG-I-bound endogenous RNA stimulated the RIG-I(H830A)Figure 2. Immune Tolerance of 20O-Methylated cap1 Structures Is Med
(A) Wild-type or indicated full-length human RIG-I mutants (see also Figure
5 nM synthetic 50-ppp-ss or dsRNA. IP10 production was analyzed 20 hr af
mean values + SEM.
(B) Immunoblot of RIG-I(WT) and indicated RIG-I mutants overexpressed in HEK
(C) Interaction of H830 with 20OH of N1 as revealed from crystal structure (Wang
(D) RIG-I(WT) or RIG-I(H830A) was overexpressed in HEK293blue cells and stimul
analyzed 20 hr after stimulation. Data from three independent experiments are
9 ng/ml IP10 in average).
(E–G) Homogenous interaction assay (AlphaScreen) of purified RIG-I(WT) or RIG-
kept constant, and ligand concentrations were titrated. Titration plots (E and F) a
proportional to RIG-I-ligand complex concentrations. One representative experim
Error bars indicate SD. Purity of RIG-I(WT) and RIG-I(H830A) proteins are shownmutant but not RIG-I(WT) (Figure 3B, right). The RIG-I-stimulating
activity of isolated endogenous RNA was partially sensitive to
alkaline phosphatase (AP), which hydrolyzes free phosphates,
and to treatment with tobacco acid pyrophosphatase (TAP),
which hydrolyzes the triphosphate bridge of mRNA caps (Fig-
ure S3A). However, only the combined treatment abolished
RIG-I stimulation, indicating the presence of stimulatory capped
and uncapped pppRNA species (Figure 3B). It was reported that
mRNA cap1 20O-methylation occurs in the nucleus and is per-
formed by the endogenous cap1 methyltransferase MTr1 (Be´-
langer et al., 2010; Perry and Kelley, 1976). To study the impact
of diminished 20O-methylation of endogenous RNA transcripts,
we knocked down hMTr1 in primary human fibroblasts (Figures
3C and S3B). Intriguingly, inhibition of endogenous cap methyl-
ation induced a substantial type I IFN response 72 hr after hMTr1
knock down (Figure 3C). Correspondingly, siRNA-mediated
knock-down of MTr1 induced IFN-bmRNA in primed A549 cells
(Figure 3D). By contrast, RIG-I-deficient A549 cells did not
upregulate IFN-b upon depletion of MTr1 (Figures 3D and
S3C). A similar scenario held true in HEK293blue cells silenced
for hMTr1 (Figures 3E and S3D) and lacking significant endoge-
nous RIG-I activity. Expression of RIG-I(WT) in combination with
knockdown of hMTr1 (Figure 3E, right) led to increased IP10
production as compared to the control setting (Figure 3E, left).
Overexpression of RIG-I(H830A) by itself also led to an increased
IP10 response, yet additional silencing of hMTr1 did not consid-
erably augment RIG-I(H830A)-induced IP10 levels (Figure 3E,
right). Altogether these results indicated that hMTr1 activity
was required for an active suppression of endogenous RNA
recognition by RIG-I.
Yellow Fever Virus cap1 20O-Methyltransferase Activity
Impairs Recognition by RIG-I
Viruses have evolved numerous mechanisms that allow capping
and methylation of viral RNA in the cytosol. Flaviviruses (positive
ssRNA) express the NS5 protein, which performs RNA polymer-
ization as well as guanine N7 and ribose 2
0O-methylations
(Figure S4; Zhou et al., 2007). To examine whether cytosolic
RNA viruses use N1-2
0O-methylation to suppress type I IFN
induction by RIG-I, we constructed a yellow fever virus replicon
(YFVR-WT) and abrogated 20O-methylation activity of NS5 by
mutation of NS5-E218 to A (YFVR-E218A) (Zhou et al., 2007);
replication was monitored by renilla luciferase activity encoded
by YFVR (Figure S4B). YFVR-E218A (no cap1 methylation
of RNA) replication was strongly impaired in A549 cells as
compared to the YFVR-WT (Figure 4A, WT versus 218). Byiated by H830 in the ppp-dsRNA Binding Cleft of RIG-I
S1) were overexpressed for 12 hr in HEK293blue cells and stimulated with
ter stimulation. Data from three independent experiments are depicted as
293blue cells for 48 hr.
et al., 2010) of CTD-ppp-dsRNA complex is displayed.
ated with indicated synthetic ppp-dsRNA ligands (5 nM). IP10 production was
depicted as mean values ± SEM, normalized on RIG-I(WT)+pppGA (100% =
I(H830A) protein with indicated synthetic ligands. Protein concentrations were
nd apparent dissociation constants (Kd in G) are shown. AlphaScreen units are
ent of two is shown.
in Figure S2F.
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Figure 3. H830 and cap1 20O-Methylation of RNA Prevent Recognition of Endogenous RNAs
(A) RIG-I(WT) and RIG-I(H830A) were expressed in HEK293blue cells in the absence of exogenous RIG-I stimuli and IP10 wasmonitored at indicated times (24, 48,
72 hr) after transfection. Data from three independent experiments with technical duplicates are depicted as mean values + SEM.
(B) Flag-tagged RIG-I-CTD was overexpressed in HEK293blue cells. Endogenous RNA binding to immune-precipitated RIG-I-CTD was extracted and used for
stimulation of RIG-I(WT)- and RIG-I(H830A)-expressing HEK293blue cells. Before stimulation, RNAs were treated with tobacco acid pyrophosphatase (TAP) or
alkaline phosphatase (AP) or left untreated (nt). IP10 induction values 20 hr after stimulation from three independent experiments with technical duplicates are
depicted as mean values + SEM. TAP hydrolyzes and inactivates free and capped, AP-only free triphosphate (ppp). Right panel: Ethidium bromide-stained
agarose gel of RIG-I(WT)-CTD-bound RNAs. Untreated (nt), treated with TAP, or AP.
(C) Fibroblasts isolated from human nasal conchas were transfected with control siRNA (control siRNA pool) or siRNA against hMTr1 (siRNA hMTr1 pool) and
harvested after 70 hr. RNAwas isolated and IFN-bmRNA induction relative to TBP-1 mRNA expression was determined by real-time PCR. One representative of
two experiments in triplicates is shown. Error bars indicate SD.
(D) IFN-bmRNA induction by siRNAs against hMTr1 in wild-type (WT) or RIG-I-deficient (Ddx58/) A549 cells were treated with indicated siRNAs, primed with
1,000 U/ml IFN-a, and assessed for IFN-b mRNA induction by qPCR 72 hr after siRNA transfection. Data from three independent experiments with technical
duplicates are depicted as mean values + SEM.
(E) IP10 induction in RIG-I(WT)- or RIG-I(H830A)-expressing HEK293blue cells 72 hr after treatment with control siRNA (control siRNA pool) or siRNA against hMTr1
(siRNA hMTr1 pool); linear range limit, 31 pg/ml.
Data from three independent experiments with technical duplicates are depicted as mean values ± SEM (B, D, E). For statistics, two-way ANOVA and Bonferroni
post-test was applied: *p < 0.05, **p < 0.01, ***p < 0.001. Knockdown efficiencies were determined by immunoblot (Figure S3A) of hMTr1 and real-time PCR
(Figures S3B and S3C).contrast, no difference in replication of both YFV replicons was
found in Vero cells, which lack type I IFN genes (Figure 4B, WT
versus 218). Likewise, when A549 or Vero cells were infected
with whole yellow fever virus particles (Figures 4C and 4D), the
NS5-E218A mutation impaired virus production in A549 cells to
a much higher extent (>60-fold reduction, Figure 4C) than in
Vero cells (<5-fold reduction, Figure 4D). These data indicate
that cap1methylation is involved in the immune escape of yellow
fever virus from a type I IFN-dependent host restriction system.
To further strengthen this hypothesis, we used RIG-I-deficient
and STAT1-deficient A549 cells to assess the influence on YFV46 Immunity 43, 41–51, July 21, 2015 ª2015 Elsevier Inc.replication (Figure 4E). Intriguingly, YFV-E218A reached the
same virus titer in RIG-I-deficient A549 cells as the wild-type vi-
rus. Similar to Vero cells, the replication of YFV-E218A was not
impaired in STAT1-deficient A549 cells. Viral replication was re-
flected by induction of the type I IFN response (Figure 4F). As
determined 8 hr after infection, YFV-E218A induced a 4-fold
higher IFIT1 expression than wild-type YFV. By contrast, no
considerable induction of IFIT1 was detected in RIG-I- and
STAT1-deficient A549 cells. The data demonstrate that RIG-I is
essential for type I IFN induction by YFV in A549 cells. Further-
more, these data clearly show that the ability of YFV to methylate
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Figure 4. YFV cap1 20O-Methyltransferase Prevents Immune Recognition
(A and B) Immune-competent A549 cells (A) or type I IFN gene-deficient Vero cells (B) were transfected with YFV replicon (YFVR) RNA or YFVR-E218A RNA-
deficient for viral cap1 20O-methyltransferase activity (see also Figure S4A). Replication was monitored by replicon-derived luciferase activity. Average of two
experiments in technical duplicates is shown. Error bars indicate SD.
(C and D) A549 cells (C) or Vero cells (D) were infected with whole yellow fever virus particles YFV-WT or YFV-E218A (MOI 0.01). Virus production was quantified
by plaque assay in BHK cells 24, 48, or 72 hr after infection. One representative of two experiments in technical duplicates is shown. Error bars indicate range.
(E)Wild-type, RIG-I-deficient (Ddx58/), or STAT1-deficient A549 cells were infectedwith YFV-WT or YFV-E218A (MOI 0.01) and virus production was quantified
as in (C) 72 hr after infection.
(F) Wild-type, RIG-I-deficient (Ddx58/), or STAT1-deficient A549 cells were infected with YFV-WT or YFV-E218A (MOI 1) and IFIT1 mRNA was measured 8 hr
after infection by RT-PCR.
(E and F) Average values of two experiments in technical duplicates are shown; error bars indicate SEM.
(G) Untransfected (no RIG-I, mock), RIG-I(WT)-, or RIG-I(H830A)-expressing HEK293blue cells were transfected with YFVR-WT or YFVR(218) replicon RNA. The
mean values of four experiments in technical duplicates is shown, error bars: SEM 100% = 895 ng/ml IP10 in average, linear range limit: 31 pg/ml.
(E–G) For statistics, two-way ANOVA and Bonferroni post-test were applied: **p < 0.01, ***p < 0.001.RNA (lost with the mutation E218A) reduces immunorecognition
of the virus by RIG-I and enhances viral replication. In
HEK293blue cells lacking endogenous RIG-I expression, YFVR-WT and YFVR-E218A induced IP10 only when RIG-I was
expressed (Figure 4G). Analogous to cells with reduced
endogenous MTr1 (Figure 3E), YFVR-E218A lacking the viralImmunity 43, 41–51, July 21, 2015 ª2015 Elsevier Inc. 47
N1-2
0O-methyltransferase activity induced a 3-fold higher
IP10 level than YFVR-WT in RIG-I(WT)-expressing cells (Fig-
ure 4G, RIG-I WT blue versus orange). On the other hand,
RIG-I(H830A), ignoring 20O-methylation status, induced equal
amounts of IP10 in response to YFVR-WT and YFVR-E218A (Fig-
ure 4G), up to the same level as the response to YFVR-E218A
RNA in RIG-I(WT) transfected cells.
Altogether these results demonstrated that cap1 20O-methyl-
ation of YFV RNA constitutes a viral subversion mechanism to
evade RIG-I recognition.
DISCUSSION
Posttranscriptional modification is key for the discrimination of
foreign from self nucleic acids. Using synthetic modified ppp-
RNA, we analyzed the influence of individual cap modifications
including N7 methylation and 2
0O-methylation. We found that
masking the 50 RNA triphosphate by the non-methylated
0G-cap alone did not influence RIG-I stimulation. Additional
N7-methylation of
0GpppNN-RNA, resulting in a cap0 structure
(m7GpppNN-RNA), reduced RIG-I activation, but only partially.
By contrast, 20O-methylation at the penultimate nucleotide (N1)
as found in vertebrate mRNA cap1 structures (m7GpppNmN-
RNA) abrogated RIG-I activation completely.
Because not only viral RNA but also abundant cytosolic
self-RNA molecules harbor a triphosphate at the 50 end, the
distinction of self from viral RNA is molecularly challenging.
The detection system needs to provide high sensitivity for few
viral RNA copies and immune tolerance toward highly abundant
endogenous RNA species. Based on our previous structural data
(Wang et al., 2010), we are now able to provide for the first time
themolecular mechanism of how an innate immune receptor dis-
criminates 20O-methylation of self RNA, as the RIG-I RNA bind-
ing pocket prevents binding of N1-2
0O-methylated RNA.
We found that sufficient self-tolerance necessitates several
levels of self-RNA labeling and that methylations are the decisive
modifications to prohibit recognition by RIG-I. By using chemi-
cally synthesized RNA, we are now able to dissect single
modifications independently and quantify their contributions.
Non-methylated 0G cap alone did not affect RIG-I stimulation.
This is in accordance with the ppp-dsRNA/RIG-I crystal struc-
ture (Lu et al., 2010; Wang et al., 2010) from which it can be pre-
dicted that a 0G cap does not sterically interfere with binding to
RIG-I. By contrast, N7-methylation (
m7G cap) impaired RIG-I
stimulation at low ligand concentrations but not to a full extent.
In previous studies, we found a higher inhibitory impact of the
methylguanidine (m7G) cap0 structure, which can be explained
by the in vitro transcription process used to generate these
ligands (Hornung et al., 2006; Pichlmair et al., 2006) (see Sup-
plemental Experimental Procedures for details). Additional
N7-methylation introduces a positive charge into the cap, which
weakens the interaction with the basic (positively charged)
pppRNA-binding cleft. Furthermore, m7G mediates binding to
eIF4A (Fechter and Brownlee, 2005), potentially competing
with binding to RIG-I. Both effects can reduce RIG-I activation
but are not sufficient to mediate the complete ignorance of self
50-triphosphate RNA by RIG-I. Our data show that complete
self-tolerance is accomplished by a single 20O-methyl group at
the 50-terminal residue (N1), a characteristic molecular feature48 Immunity 43, 41–51, July 21, 2015 ª2015 Elsevier Inc.of higher eukaryotes’ mRNA (Banerjee, 1980). This immune toler-
ance is mediated by a single highly conserved amino acid, H830,
in the pppRNA-binding domain of RIG-I. The responsible histi-
dine is present in all known species that express RIG-I and
was therefore deemed to be involved in RNA binding (Lu et al.,
2010; Wang et al., 2010). Mutation of H830 to alanine restored
the binding of and stimulation by 20O-methyl pppRNA while
the stimulatory activity of non-methyl pppRNA remained unaf-
fected, highlighting an exclusive immune regulatory function of
H830. N1-2
0O-methylated and non-methylated ppp-dsRNAs
or m7Gppp-dsRNA bind with considerably different affinities
to wild-type RIG-I but with similar affinities to mutant RIG-
I(H830A), indicating a direct steric effect of H830 on N1-2
0O-
methylated RNA. An inactive ligand (pppGmA) still showed resid-
ual but non-productive RIG-I binding. The discrepancy between
binding (only 5-fold reduction) and biological activity (no RIG-I
activation at any concentration) might appear contradictory at
first view. However, an assay that simply measures binding affin-
ity can resolve neither the site nor the orientation of protein/
ligand interaction. Previously, non-productive binding to RIG-I
of dsRNAwith competitive, ppp(+1nt)-dsRNA, and non-compet-
itive, blunt OH-dsRNA, ligands has been reported (Marq et al.,
2011). Our competition assay revealed that N1-2
0O-methylated
dsRNA is a much weaker competitive inhibitor than ppp(+1nt)-
dsRNA (if at all) for pppGA binding. Thus, pppGmA has a similar
profile to the blunt OH-dsRNA sequences used by Marq et al.
(2011). These sequences can bind RIG-I but are nonetheless
incapable of inhibiting pppGA binding or inducing type I IFN. In
retrospect, because both blunt OH-dsRNA and pppGmA cannot
properly interact with the lysine-rich binding cleft, the similarities
observed between these two classes of dsRNA are completely in
line with our other data. Although we demonstrate that pppGmA
is sterically hindered byH830, OH-dsRNA clearly lacks the phos-
phates requisite for binding-cleft interaction. By contrast,
ppp(+1nt)-dsRNA should be able to interact with the designated
binding cleft (K888, K858, K861, H830, K907), and it could be
that this is essential to its ability to act as a competitive, non-pro-
ductive ligand. Nonetheless, from our data we cannot conclude
whether the detected pppGmA/RIG-I interaction results from an
inaccurate binding as a result from a distorted helix orientation
within the binding cleft or whether interaction is mediated by
other, unspecific contacts. Whatever the nature of this interac-
tion, it does not succeed in RIG-I activation.
In addition, it must be emphasized that the in vivo N1-methyl-
ation ofmRNAdoes not occur in an isolated fashionwithout m7G-
capping. In fact, MTr1 requires m7G-capped RNA as a substrate.
Moreover, in this physiological situation, these twomodifications
are strongly synergistic. m7G-capping mediates a reduction in
type I IFN induction for RIG-I(WT) and RIG-I(H830A) alike, and
additional N1-methylation of
m7G-capped dsRNA (m7GpppGmA)
completely abrogates the interaction with RIG-I(WT). Thus,
in vivo, it is MTr1-mediated N1-methylation that renders endog-
enous mRNA completely immunologically inert.
Because RIG-I is exclusively stimulated by base-paired
pppRNA ends (Schlee et al., 2009), the existence of endogenous
RIG-I ligands is not self-evident. Although we did not identify the
RNA species responsible for RIG-I activation, our results demon-
strate that endogenous RNA species exist, which can be de-
tected in the absence of N1-2
0O-methylation or the RIG-I H830
side chain. Phosphatase treatment of endogenous RNA re-
vealed that in the cell both capped and uncapped RNA mole-
cules exist that stimulate mutant RIG-I(H830A). Base-paired
RNA structures can be a result of intra- or intermolecular base
pairing or could be formed by a recently described endogenous
RNA replication mechanism (Kapranov et al., 2010). The fact that
stimulation of RIG-I(H830A) by endogenous RNA was relatively
weak indicates that the concentration of stimulatory RIG-I li-
gands is either low or that endogenous RIG-I ligands present a
suboptimal ligand structure. However, its long-term immune
stimulatory effects could lead to severe autoinflammatory effects
in vivo.
Our results on the YFV-encoded 20O-methyltransferase
demonstrate that viruses employ 20O-methylation of N1 to
escape recognition by RIG-I: the 20O-methyltransferase deletion
mutant YFVR-E218A of the viral replicon led to decrease of
replication in A549 cells but not in Vero cells, which are known
to have deleted IFN genes. Accordingly, the replication of the
mutated virus YFV-E218A was strongly impaired in A549 cells
but not in Vero- or STAT1-deficient A549 cells, which have a
defect in type I IFN signaling. Intriguingly, viral titers of YFV-
E218A and YFV-WT were equal in RIG-I-deficient A549 cells.
IFIT1 mRNA (as an indicator of type I IFN induction) was induced
more strongly by YFV-E218A than YFV-WT. Of note, no IFIT1 in-
duction by YFV-WT or YFV-E218A occurred in absence of RIG-I
in A549 cells.
Analogous to our YFV 20O-methyltransferase mutant YFV-
E218A, Daffis et al. (2010) analyzed the flavivirus WNV including
a mutant lacking 20O-methyltransferase activity (WNV-E218A).
They showed that the type I IFN-induced protein IFIT1 mediates
repression of WNV-E218A replication in the brain (in vivo) and in
macrophages in vitro (Daffis et al., 2010). As revealed by their ex-
periments, the type I IFN-induced IFIT1 protein could act only
downstream of MAVS-dependent type I IFN-inducing pathways,
which in turn requires prior detection of the viral RNA via either
RIG-I or MDA5 (Daffis et al., 2010). In a follow-up study, the
same group observed that Ifit/mice still survive subcutaneous
WNV-E218A infection at a viral titer that is lethal for wild-type
WNV (Szretter et al., 2012), suggesting 20O-methylation-sensi-
tive immune mechanisms beyond IFIT1. Altogether, this is in
line with our results that RIG-I is a 20O-methylation-sensitive
receptor of viral RNA and that IFIT1 expression is induced by
RIG-I and therefore cannot act without prior upregulation by
type I IFN-inducing receptors like RIG-I.
Zu¨st et al. (2011) observed that a mutant of the (+)ssRNA co-
ronavirus MHV lacking viral N1-2
0O-methyltransferase activity
showed enhanced IFN-b induction and suppressed virus replica-
tion in murine macrophages and that both effects were MDA5
dependent. However, MDA5 deficiency neither led to restoration
of WNV-E218A infectivity in primary cells nor rescued WNV-
E218A virulence in mice (Szretter et al., 2012). In addition, a viral
mRNA has been identified, which stimulated MDA5, when ex-
pressed under the control of an RNA polymerase-II-controlled
promoter that produces N1-2
0O-methylated mRNA (cap1 struc-
ture) (Luthra et al., 2011), which suggests that N1-2
0O-methyl-
ation does not generally impair MDA5 engagement. None of
the above studies examined RIG-I-deficient cells. In the light of
our results and the above mentioned data (Daffis et al., 2010;
Szretter et al., 2012), we conclude that IFIT1 acts as type I IFN-induced effector downstream of type I IFN-inducing receptors
(e.g., RIG-I and MDA5) to sequester viral mRNA from translation
(Habjan et al., 2013). Because no direct impact of N1-2
0O-
methylation on binding of viral RNA to MDA5 was shown, still
an indirect effect remains possible. Because coronavirus recog-
nition in murine macrophages is known to require MDA5 (Roth-
Cross et al., 2008), it is conceivable that stimulation via MDA5
is required for type I IFN-dependent upregulation of IFIT1, which
then sequesters non-20O-methyl RNA, thereby inhibiting trans-
lation of viral proteins, which suppress recognition of RNA or
interfere with type I IFN-inducing pathways. In this study, we pro-
vide molecular evidence for a direct physical interaction of RIG-I
and RNA, which is sterically impaired by 20O-methyl at the N1
position, leading to abolishment of RIG-I activation.
In conclusion, with this study we identified the highly
conserved biological function of the N1-2
0O-methylation of cap-
ped RNA, and we resolved the molecular mechanism that allows
the distinction of self versus foreign RNA by RIG-I. We provide
evidence that endogenous stimulatory RNA molecules exist at
sufficient numbers to allow RIG-I activation and that the proper
function of the endogenous 20O-methyltransferase prevents
RIG-I-driven autoinflammation; furthermore, that viruses mimic
the molecular mechanism of self-tolerance by introducing a
viral 20O-methyltransferase. To our knowledge, RIG-I is the first
example of an innate immune receptor that adapted its structure
to tolerate self-RNA (that is actively labeled self in the nucleus)
rather than adapting its structure to detect a specific foreign
molecule. Thus, like the adaptive immune system, innate immu-
nity employs active mechanisms that secure tolerance toward
self while potently responding to foreign molecular pattern. Our
study emphasizes endogenous RNA methyltransferases (N7
and N1/2-2
0O-methyltransferases) as the crucial safeguards for
maintenance of immune tolerance of self-RNA.EXPERIMENTAL PROCEDURES
Preparation of Capped RNA
Triphosphorylated RNA oligonucleotides were chemically synthesized as
described (Goldeck et al., 2014). Internal methylation occurred by incorpora-
tion of methylated nucleotides during chemical synthesis. Capping (addition
of 50 7mG) occurred by incubation of pppRNA with vaccina virus capping
enzyme (Epicenter), GTP, and S-Adenosyl methionine (SAM) according to
the manufacturers’ protocol (Figure S2). Preparation of ‘‘GpppGA’’ occurred
in absence of SAM. Uncapped pppRNA was eliminated by treatment with
50-polyphosphatase (Epicenter) and Terminator Nuclease (Epicenter) (Fig-
ure S2). Polyacrylamide gel electrophoresis (PAGE) and MALDI-ToF mass
spectrometry (Metabion) was performed as described (Figure S2; Schlee
et al., 2009).
Cell Culture
Human PBMCs were isolated as described (Schlee et al., 2009). For stimula-
tion, 43 106 cells (PBMCs) were cultured in 96-well plates. The PBMC studies
were approved by the local ethics committee (Ethikkommission der Medizini-
schen Fakulta¨t Bonn) according to the ICH-GCP guidelines. Written informed
consent was provided by voluntary blood donors.
To inhibit TLR7/8 activity, cells were pre-incubatedwith 2.5 mg/ml chloroquine
for 30min.Cellswerekept inRPMI1640 (10%FCS,1.5mML-Glu, 100U/mlpen-
icilin, 100 mg/ml streptomycin). For transfection, nucleic acids were complexed
with Lipofectamine(LF) 2000 (Life Technologies). HEK293blue cells (Invivogen)
are reporter cells for type 1 IFN. By incident, as demonstrated (Figures 2A and
2D), they show negligible RIG-I background activity. Murine BM-DCs were
generated by culturing murine bone marrow cells for 7 days with GM-CSF.Immunity 43, 41–51, July 21, 2015 ª2015 Elsevier Inc. 49
Detection of Cytokines
IFN-a and IP10 levels were analyzed with commercial ELISA assay kits. In our
hands the linear range limit for the IP-10 ELISA (BD Biosciences) was 31 pg/ml
and for the IFN-a ELISA (eBioscience) was 8 pg/ml.
Generation of RIG-I Mutants
Mutagenesis of full-length RIG-I was performed as described (Wang et al.,
2010). (Primers listed in Table S1.) Constructs were confirmed by sequencing.
Equal protein expression of RIG-I mutants was confirmed by immunoblot with
an antibody against Flag (Sigma) (Figure 2B).
Protein Purification and Analysis
(His6)-Flag-tagged RIG-I(WT) and RIG-I(H830A) were transiently overex-
pressed in HEK293blue cells and lysed in a CHAPS-containing lysis buffer
(150 mMNaCl, 50 mM Tris/HCl [pH 7.4], 2 mMMgCl2, 1 mMDTT, 1%CHAPS)
including protease inhibitor cocktail (Roche). The lysate was incubated over-
night at 4C with anti-FLAG beads (Sigma). Anti-FLAG beads were washed
subsequently with lysis buffer and high salt wash buffer (300 mM NaCl,
50 mM Tris/HCl [pH 7.4], 5 mM MgCl2, 1 mM DTT, 0.1% CHAPS). RIG-
I-FLAG was eluted by addition of FLAG-peptide (300 mg/ml) solution to the
beads. The purity and concentration of recombinant RIG-I-derivates was
determined by SDS-PAGE/Coomassie blue stain.
Alpha Screen RIG-I-Binding Assay
The binding affinity of RNA for (His6)-FLAG-tagged RIG-I and RIG-I(H830A)
was determined by an amplified luminescent proximity homogenous assay
(AlphaScreen; Perkin Elmer). In this assay purified HF-RIG-I was incubated
with concentrations of biotinylated RNA for 1 hr at 37C in buffer (50 mM
KCl, 5 mM HEPES [pH 7.0], 3 mM MgCl2, 0.5 mM DTT, 0.01% Tween, 1%
BSA) and subsequently incubated for 30 min at 25C with HF-RIG-I-binding
Nickel Chelate acceptor beads (Perkin-Elmer) and biotin-RNA-binding Strep-
tavidine donor beads (Perkin Elmer).
Pull-Down of Endogenous RNA by RIG-I-CTD
For theaffinitypurificationofendogenousRNA,aRNApull-downwasconducted
using the RNA-binding domain CTD. A RIG-I-CTD expression plasmid contain-
ing a (His6)-Flag-Tagwas generated via PCRcloning. RIG-I-CTDwas transiently
overexpressed in HEK293blue cells and lysed concordant to the protein purifica-
tion protocol (see above). The lysate was incubated 2 hr at 4C with anti-FLAG
beads (Sigma). The beadswere washed stringently with lysis buffer. Trizol/chlo-
roformextractionof the boundRNA from theRIG-I-CTDand treatmentwith alka-
line phosphatase (AP; Fermentas) and tobacco acid pyrophosphatase (TAP;
Epicenter) was conducted according to manufacturers’ instructions.
siRNA-Mediated Knockdown Experiments
ForRNAi/RIG-Imutant experiments, 153103HEK293bluecellswereseededper
well (96-well format) and 50 ngRIG-I expressionplasmid (WTorH830A) perwell
was transfected with Genejuice (Merck). After 12 hr, 100 nM siRNA against
sihMTr1 or control (siGenome SMART pool, Dharmacon) was transfected with
LF2000. WT or Ddx58/ A549 cells were seeded at 30 3 103/well (48-well
format) and transfected (RNAiMAX, Life Technologies) with siRNAs against
hMTr1 or luciferase (target site + 30dTdT: siLuc: cauaaggcuaugaagagauac,
sihMTr1#1: gugaaggauuggguaaaua, sihMTr1#2: ggaaaugagcgauuggaug, Bio-
mers). Efficient knockdown was confirmed via qPCR (Figure S3).
Construction of Yellow Fever Virus Constructs and Quantification of
Replication
The construction of YFV wild-type and NS5 E218A mutant virus and replicons
(Figure S4) expressing renilla luciferase is described in the Supplemental
Experimental Procedures. In brief, replication-competent YFVR- or YFV-RNA
were generated by in vitro transcription. Replication of YFV-replicons was
monitored by renilla-Luciferase assay 24 hr after transfection. Virus was gener-
ated by electroporation of BHK-J cells with YFV-RNA. Virus titers were deter-
mined by BHK-J cell plaque assays as described (Ku¨mmerer and Rice, 2002).
Generation of Knockout Cell Lines
A549 cells were transfected with LF2000 with 200 ng of a CAS9-gRNA expres-
sion plasmid targeting RIG-I (50-GGGTCTTCCGGATATAATCC(TGG)-30) or50 Immunity 43, 41–51, July 21, 2015 ª2015 Elsevier Inc.STAT1 (50-CAGGAGGTCATGAAAACGGA(TGG)-30). Knockout clones were
confirmed by functional testing, immunoblot, and Sanger sequencing.
SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures, one table, and Supplemental
Experimental Procedures and can be found with this article online at http://dx.
doi.org/10.1016/j.immuni.2015.06.015.
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